Pharmacology of GLP-1 Receptor Agonists
GLP-1 receptor agonists are modified peptide analogs designed to resist rapid degradation by dipeptidyl peptidase-4, achieving extended half-lives through molecular modifications including albumin binding, immunoglobulin conjugation, or microsphere encapsulation, with dosing ranging from twice-daily to once-weekly administration depending on the specific agent. 1
Mechanism of Action
GLP-1 receptor agonists work through multiple pathways that extend beyond simple glucose control:
Pancreatic Effects
- Glucose-dependent insulin secretion: Activation of G-protein coupled GLP-1 receptors increases intracellular calcium in pancreatic β-cells, triggering insulin exocytosis 1
- Glucagon suppression: Inhibits glucagon secretion from α-cells (only 10-15% of α-cells express GLP-1 receptors) 1
- Low hypoglycemia risk: Both effects are glucose-dependent and significantly attenuated when plasma glucose is not elevated 1
- β-cell protection: May promote β-cell proliferation and protect against apoptosis 1
Gastric and Gastrointestinal Effects
Much of the glucose-lowering effect comes from delayed gastric emptying rather than pancreatic effects 1. The mechanism involves:
- Inhibition of gastric peristalsis while increasing pyloric tone 1
- Vagal nerve mediation (effects absent in patients post-vagotomy) 1
- Activation of nitrergic pathways in the myenteric plexus 1
- Reduced gastric acid secretion and increased fasting/postprandial gastric volumes 1
Critical clinical point: Scintigraphy studies demonstrate persistent delayed gastric emptying with exenatide, liraglutide, and semaglutide in patients with diabetes and obesity 1. This has major peri-operative implications for aspiration risk.
Central Nervous System Effects
GLP-1 receptors in the hypothalamus (arcuate nucleus) and brainstem (area postrema, nucleus tractus solitarius) mediate:
- Appetite suppression and enhanced satiety 1
- Meal termination signals 1
- Energy expenditure regulation 1
Cardiovascular Effects
GLP-1 receptors localized primarily to the sinoatrial node and arterial walls provide cardioprotection through 1:
- Improved myocardial substrate utilization
- Anti-inflammatory and anti-atherosclerotic effects
- Reduced myocardial ischemia injury
- Lower systemic and pulmonary vascular resistance
- Improved lipid profiles
The LEADER trial demonstrated 13% relative risk reduction in cardiovascular death, non-fatal MI, or stroke (13% vs 14.9%, p=0.01) 1. The SUSTAIN 6 trial confirmed this with semaglutide (6.6% vs 8.9%, RR 0.74) 1.
Pharmacokinetics
Molecular Modifications to Extend Half-Life
Native GLP-1 has a half-life of only ~2 minutes due to rapid dipeptidyl peptidase-4 cleavage 1. Different agents achieve prolonged action through:
- Exenatide: 50% homology with GLP-1, resistant to dipeptidyl peptidase-4 cleavage 1
- Semaglutide: Liraglutide analog with greater albumin affinity 1
- Albiglutide: Non-covalent conjugation with albumin 1
- Dulaglutide: Conjugation with immunoglobulin G fragment crystallizable region 1
- Long-acting exenatide: Drug encapsulated in microspheres for gradual subcutaneous release 1
Classification by Duration of Action
Short-acting agents (exenatide, lixisenatide):
- Administered once or twice daily
- Primarily lower postprandial glucose through gastric emptying inhibition 2
- More pronounced effect on delaying gastric emptying with acute/intermittent exposure 1
Long-acting agents (liraglutide, dulaglutide, semaglutide, albiglutide):
- Administered once daily to once weekly
- Stronger effect on fasting glucose through insulinotropic and glucagonostatic actions 2
- Continuous receptor activation at recommended doses 2
Tachyphylaxis Considerations
Important nuance: While vagal activity (measured by pancreatic polypeptide) shows tachyphylaxis with continuous GLP-1 exposure, delayed gastric emptying persists 1. Studies using paracetamol absorption tests suggested tachyphylaxis with long-acting semaglutide, but this test is now considered suboptimal—scintigraphy (gold standard) demonstrates persistent gastric emptying delay 1.
Dosing Regimens
FDA-Approved Dosing 1
Liraglutide (daily):
- Start: 0.6 mg daily × 1 week
- Then: 1.2 mg × 1 week
- Target: 1.8 mg daily
- For obesity: 3 mg daily (approved 2014)
Semaglutide injectable (weekly):
- Start: 0.25 mg weekly × 4 weeks
- Then: 0.5 mg × 4 weeks
- Target: 1 mg weekly
- For obesity: 2.4 mg weekly (approved 2021)
Semaglutide oral:
- Start: 3 mg × 30 days
- Then: 7 mg × 30 days
- Target: 14 mg daily
Dulaglutide (weekly):
- 0.75 mg OR 1.5 mg subcutaneously weekly
Tirzepatide (dual GIP/GLP-1 agonist):
- Doses up to 15 mg weekly
- Achieved 20.9% weight loss at highest dose 1
Indications
- Type 2 diabetes: All agents approved
- Obesity: Liraglutide 3 mg daily and semaglutide 2.4 mg weekly approved for BMI >30, or >27 with comorbidities (type 2 diabetes, hypertension, obstructive sleep apnea) 1
Metabolism and Excretion
- Native GLP-1: Cleaved rapidly by dipeptidyl peptidase-4 into GLP-1 (9-36) amide, eliminated renally, half-life ~2 minutes 1
- GLP-1 receptor agonists: Modified to resist cleavage, with varying metabolism profiles affecting choice in renal impairment 3
- Renal function: Diminished kidney function attenuates glucose-lowering effects of some agents but cardiorenal protection maintained with eGFR >20-25 mL/min/1.73 m² 4
Adverse Effects
Gastrointestinal (Most Common) 1, 4
| Adverse Effect | Management Strategy |
|---|---|
| Nausea and vomiting | Avoid in gastroparesis; start low dose and titrate slowly |
| Dyspepsia | Slow upward titration |
| Diarrhea | Reduce meal size |
| Gastrointestinal reflux | Limit alcohol and carbonated drinks |
| Constipation | Avoid high-fat diet |
Key mitigation strategies 4:
- GI symptoms most prominent at initiation, usually improve over time
- Slow titration critical for tolerability
- Smaller meals, stop eating when not hungry, avoid spicy foods
- More common with short-acting than long-acting agents 1
- Discontinue DPP-4 inhibitors when adding GLP-1 RA (redundant incretin-based therapies) 4
Serious Adverse Effects
Pancreatitis:
- Rare but reported with exenatide 1
- American Association of Clinical Endocrinologists recommends caution in patients with history of pancreatitis 1
- Long-term trials have largely dispelled concerns about pancreatic cancer 5
Retinopathy:
- SUSTAIN 6 trial showed increased retinopathy events with semaglutide 4
- Due to rapid glucose-lowering in patients with marked hyperglycemia and preexisting retinopathy (phenomenon previously seen with insulin) 4
- Management: Regular eye examinations in high-risk patients; long-term glucose control benefits outweigh acute risk 4
Gallbladder disorders:
- Can occur but unusual to be symptomatic 1
Cardiac arrhythmia/tachycardia:
- If symptomatic, monitor and consider beta-blockers 1
Thyroid concerns:
- May confer increased risk for thyroid cancer 5
- Vigilance required
Gastric retention and aspiration risk:
- Slowing of gastric emptying increases propensity for retained gastric contents 5
- Increased risk during upper GI endoscopy or general anesthesia 5
- Critical caveat: Risk may be elevated in long-standing T2D even without GLP-1 RA treatment 5
Muscle and bone mass loss:
- Adverse effects may include loss of muscle and bone mass 6
- Functional implications require further study 6
Hypoglycemia Risk
Low risk when used alone due to glucose-dependent mechanism 1. However:
- Evaluate and readjust insulin secretagogues and insulin when initiating GLP-1 RA 4
- Risk increases when combined with sulfonylureas or insulin
Genital Mycotic Infections
- Most common adverse effect of SGLT2 inhibitors (when used in combination) 4
- Women (10-15% risk), those with previous GMI, uncircumcised men at highest risk
- Managed with antifungal drugs, rarely requires discontinuation
Antibody Formation
- As protein-based therapies, may induce antibody formation 3
- May attenuate therapeutic efficacy and affect safety
Contraindications and Precautions
Absolute contraindications:
- Gastroparesis 1
- Personal or family history of medullary thyroid carcinoma (based on preclinical data)
- Multiple endocrine neoplasia syndrome type 2
Use with caution:
- History of pancreatitis 1
- Preexisting retinopathy (requires ophthalmologic monitoring before initiation) 4
- Peri-operative period (consider holding due to gastric retention risk)
- Renal impairment (agent selection matters) 3
Clinical Efficacy
Weight Loss
Non-diabetic patients achieve greater weight loss (6.1-17.4%) compared to diabetic patients (4-6.2%) 1.
- STEP trial: Semaglutide 2.4 mg weekly reduced mean body weight by 14.9% in non-diabetic, overweight/obese patients 1
- Tirzepatide: 15% weight loss at 72 weeks (20.9% at 15 mg dose) 1
- This degree of weight loss previously only reported with bariatric surgery 1
Cardiovascular Outcomes
- LEADER trial (liraglutide): 13% RR reduction in CV death, non-fatal MI, or stroke 1
- SUSTAIN 6 (semaglutide): 26% RR reduction in same composite endpoint 1
- Recent trial in non-diabetic patients with pre-existing CVD and BMI >27: Semaglutide 2.4 mg reduced primary CV endpoint from 8.2% to 6.5% (p=0.001) 1
- Stroke reduction strongest with GLP-1 RAs compared to SGLT2 inhibitors 4
Renal Protection
Large-scale trials show GLP-1 RAs slow progression to renal failure in high-risk patients with type 2 diabetes 6